Risk factors
Roivant Sciences (ROIV) risk factors
Item 1A of every Roivant Sciences Ltd. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors98 risks18 new22 dropped33 reworded
Foreign-CMO restrictions, including the BIOSECURE Act, could disrupt manufacturing, supply chains and clinical programs.
Filed May 20, 2026 - FY2025 10-K risk factors102 risks
Roivant Sciences is a clinical-stage biopharmaceutical company with a unique Vant business structure and limited operating history. Key risks involve clinical trial uncertainty, reliance on product acquisitions and licensing, regulatory compliance, and extensive capital allocation. The company holds significant cash and marketable securities subject to macroeconomic conditions.
Filed May 29, 2025